Eva Laker
YOU?
Author Swipe
View article: Dolutegravir-associated hyperglycemia: a narrative review
Dolutegravir-associated hyperglycemia: a narrative review Open
Dolutegravir is a preferred antiretroviral drug given its high resistance barrier and efficacy; however, reports from sub-Saharan Africa indicate increased hyperglycemia rates among individuals living with HIV on dolutegravir. Potential me…
View article: Cerebral Perfusion Pressures and Implications on Clinical Outcomes and Medical Management in Cryptococcal Meningitis
Cerebral Perfusion Pressures and Implications on Clinical Outcomes and Medical Management in Cryptococcal Meningitis Open
Background In cryptococcal meningitis, increased intracranial pressure (ICP) is associated with worse outcomes and increased mortality. We sought to understand how changes in ICP and mean arterial pressure (MAP) affect cerebral perfusion p…
View article: “Injectable ARVs will give me peace” women’s acceptability of injectable antiretroviral therapy in prevention of HIV vertical transmission in Uganda
“Injectable ARVs will give me peace” women’s acceptability of injectable antiretroviral therapy in prevention of HIV vertical transmission in Uganda Open
View article: Associations with HIV preexposure prophylaxis use by cisgender female sex workers in two Ugandan cities
Associations with HIV preexposure prophylaxis use by cisgender female sex workers in two Ugandan cities Open
Background Sex workers of all genders have a high risk of HIV acquisition and are a priority population for HIV pre-exposure prophylaxis (PrEP). We aimed to assess current oral PrEP use and associated factors among cisgender female sex wor…
View article: Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa
Ethical issues surrounding the implementation of long-acting injectable antiretroviral therapy in sub-Saharan Africa Open
Background This article discusses the ethical issues surrounding the integration of long-acting injectable antiretroviral therapy (LA-ART) in the programmatic management of human immunodeficiency virus (HIV). As the medical landscape evolv…
View article: A programmatic assessment of dolutegravir adverse events and discontinuations in <scp>Uganda</scp>
A programmatic assessment of dolutegravir adverse events and discontinuations in <span>Uganda</span> Open
Introduction Dolutegravir is now extensively used in sub‐Saharan Africa as a preferred component of antiretroviral therapy (ART). There is a paucity of large studies using routinely collected data from African people living with HIV on dol…
View article: Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol
Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol Open
Introduction Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for TB preventive therapy (TPT), challenges persist, including incompletion of treatment and adverse drug reactions (ADRs). There…
View article: Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks Open
View article: Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa
Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa Open
Long‐acting injectable (LAI) cabotegravir and rilpivirine for HIV treatment and LAI cabotegravir for pre‐exposure HIV prophylaxis are being rolled out in a multitude of countries worldwide. Due to the prolonged exposure, it can be challeng…
View article: Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study Protocol
Clinical Predictors of 3-Months Isoniazid Rifapentine (3HP) - Related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy. (PAnDoRA-3HP study): An Observational Study Protocol Open
Introduction Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for Tuberculosis Preventive Therapy (TPT), challenges persist, including incompletion of treatment and adverse drug reactions (AD…
View article: Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda
Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda Open
View article: Clinical Pharmacology considerations and drug-drug interactions with long-acting cabotegravir and rilpivirine relevant to a sub-Saharan Africa
Clinical Pharmacology considerations and drug-drug interactions with long-acting cabotegravir and rilpivirine relevant to a sub-Saharan Africa Open
Long-acting injectable (LAI) cabotegravir and rilpivirine for HIV treatment and LAI cabotegravir for pre-exposure HIV prophylaxis are being rolled out in a multitude of countries worldwide. Due to the prolonged exposure, it can be challeng…
View article: Alcohol use disorder among people diagnosed with Tuberculosis in a large urban case-finding project in central Uganda: prevalence, associated factors and challenges to treatment adherence
Alcohol use disorder among people diagnosed with Tuberculosis in a large urban case-finding project in central Uganda: prevalence, associated factors and challenges to treatment adherence Open
Background Heavy consumption of alcohol increases the risk of developing active tuberculosis (TB), contributes to delayed diagnosis and affects adherence to treatment. Within a large urban case-finding project, we aimed to determine the pr…
View article: Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy study
Development and validation of quantitative PCR assays for HIV-associated cryptococcal meningitis in sub-Saharan Africa: a diagnostic accuracy study Open
European and Developing Countries Clinical Trials Partnership; Swedish International Development Cooperation Agency; Wellcome Trust/UK Medical Research Council/UKAID Joint Global Health Trials; and UK National Institute for Health Research.
View article: 5-Flucytosine Longitudinal Antifungal Susceptibility Testing of <i>Cryptococcus neoformans</i>: A Substudy of the EnACT Trial Testing Oral Amphotericin
5-Flucytosine Longitudinal Antifungal Susceptibility Testing of <i>Cryptococcus neoformans</i>: A Substudy of the EnACT Trial Testing Oral Amphotericin Open
Background The EnACT trial was a phase 2 randomized clinical trial conducted in Uganda, which evaluated a novel orally delivered lipid nanocrystal (LNC) amphotericin B in combination with flucytosine for the treatment of cryptococcal menin…
View article: Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults Open
View article: Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks Open
View article: Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults Open
Background The Uganda Ministry of Health issued restrictive guidelines on the use of dolutegravir (DTG) in persons stratified to have a heightened risk of diabetes mellitus. This followed multiple reports of persons with HIV (PWH) presenti…
View article: Alcohol use disorder among patients diagnosed with Tuberculosis in a large urban case-finding project in central Uganda: prevalence, associated factors and lived experiences
Alcohol use disorder among patients diagnosed with Tuberculosis in a large urban case-finding project in central Uganda: prevalence, associated factors and lived experiences Open
Background Heavy consumption of alcohol increases the risk of developing active tuberculosis (TB), contributes to delayed diagnosis and affects adherence to treatment. Within a large urban case-finding project, we sought to determine the p…
View article: Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir Open
Background Following reports of anti-retroviral therapy (ART) experienced Ugandan people living with HIV (PLHIV) presenting with diabetic ketoacidosis weeks to months following a switch to dolutegravir (DTG), the Uganda Ministry of Health …
View article: Prevalence of overweight and obesity and associated factors among people living with HIV attending a tertiary care clinic in Uganda
Prevalence of overweight and obesity and associated factors among people living with HIV attending a tertiary care clinic in Uganda Open
Background: Overweight and obesity are significantly increasing among people living with HIV (PLWH), contributing to the risk of major adverse cardio-metabolic events. However, little is known on its prevalence among PLWH in sub-Saharan Af…
View article: 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study Open
Unitaid.
View article: Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda
Factors associated with uptake of contraceptives among HIV positive women on dolutegravir based anti-retroviral treatment-a cross sectional survey in urban Uganda Open
Background In May 2018, following the preliminary results of a study in Botswana that reported congenital anomalies in babies born to HIV-positive women taking dolutegravir drug, the WHO issued a teratogenicity alert. However, there are sc…
View article: Association of Hyponatremia on Mortality in Cryptococcal Meningitis: A Prospective Cohort
Association of Hyponatremia on Mortality in Cryptococcal Meningitis: A Prospective Cohort Open
Background Sodium abnormalities are frequent in central nervous system infections and may be caused by cerebral salt wasting, syndrome of inappropriate antidiuretic hormone secretion, or medication adverse events. In cryptococcal meningiti…
View article: Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial Open
Janssen.
View article: Factors associated with poor social support among Persons Living with HIV/AIDS at the Infectious Disease Institute HIV/AIDS clinic in Uganda, 2019: A cross-sectional study
Factors associated with poor social support among Persons Living with HIV/AIDS at the Infectious Disease Institute HIV/AIDS clinic in Uganda, 2019: A cross-sectional study Open
Background Social support is known to influence desired health outcomes resulting in decrease in morbidity and mortality. HIV patients with poor social support are at risk of worse health outcomes. Little is known about the determinants of…
View article: High Prevalence of Clinical Jaundice Associated with Poor Adherence Among Adults on Boosted Atazanavir Antiretroviral Therapy Regimen at the Infectious Disease Institute HIV/AIDS Clinic in Kampala, Uganda
High Prevalence of Clinical Jaundice Associated with Poor Adherence Among Adults on Boosted Atazanavir Antiretroviral Therapy Regimen at the Infectious Disease Institute HIV/AIDS Clinic in Kampala, Uganda Open
Background Boosted atazanavir (ATV/r)-based Antiretroviral Therapy (ART) regimen is recommended by the World Health Organization (WHO) as second line treatment for HIV/AIDS. ATV/r is known to cause clinical jaundice, which may lead to non-…
View article: Prevalence of Overweight And Obesity And Associated Factors Among People Living With Hiv Attending A Tertiary Care Clinic In Uganda
Prevalence of Overweight And Obesity And Associated Factors Among People Living With Hiv Attending A Tertiary Care Clinic In Uganda Open
Background: Overweight and obesity are significantly increasing among people living with HIV (PLWH), contributing to the risk of major adverse cardio-metabolic events. However, little is known on its prevalence among PLWH in sub-Saharan Af…
View article: Factors Associated with Uptake of Contraceptives Among HIV Positive Women on Dolutegravir Based Anti-Retroviral Treatment - A Crossectional Survey in Urban Uganda.
Factors Associated with Uptake of Contraceptives Among HIV Positive Women on Dolutegravir Based Anti-Retroviral Treatment - A Crossectional Survey in Urban Uganda. Open
Background In May 2018, following the preliminary results of a study in Botswana that reported congenital anomalies in babies born to HIV-positive women taking dolutegravir drug, the WHO issued a teratogenicity alert. However, there are sc…
View article: The burden of drug resistant tuberculosis in a predominantly nomadic population in Uganda: a mixed methods study
The burden of drug resistant tuberculosis in a predominantly nomadic population in Uganda: a mixed methods study Open